Novel agents in treatment of acute myeloid leukemia

Lidia Gil; Mieczysław Komarnicki

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2007
vol. 11

Send email

Copy url:

abstract:

Novel agents in treatment of acute myeloid leukemia

Lidia Gil

,

Mieczysław Komarnicki

Współczesna Onkologia (2007) vol. 11; 4 (181-185)

Online publish date: 2007/06/19

View full text Get citation

Current treatment strategies of acute myeloid leukaemia based on conventional cytotoxic agents provide complete remission in 60%-80% of younger patients; however, only 30%-40% are alive at 5 years. For elderly patients significant improvements in survival have not emerged for years. Most recently, insights into the molecular pathogenesis of AML have led to the development of specific targeted therapy. This review presents new drugs being studied alone or in combination with chemotherapy: immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors, farnesyl transferase inhibitors, FLT3 inhibitors, antiangiogenic agents, apoptosis modulators, epigenetic agents and new nucleoside analogues and alkylating agent

keywords:

Novel agents in treatment of acute myeloid leukemia

Lidia Gil , Mieczysław Komarnicki

acute myeloid leukaemia, targeted therapy, immunotherapy, epigenetic agents

Lidia Gil

,

Mieczysław Komarnicki